Table 1.

Baseline characteristics of our target and control groups

	Study group (n = 85)		Control group (n = 170)
	Non DVT	DVT	Non DVT	DVT
Number of patients	74 (87%)	11 (13%)	158 (92.9%)	12 (7.1%)
Age (mean)	27–85 (61.9)	57–84 (68.4)	25–85 (62.1)	32–81 (59.7)
Sex ratio
Male/Female	33 (44.6%)/41 (55.4%)	5 (45.4%)/6 (54.6%)	71 (44.9%)/86 (55.1%)	5 (41.6%)/7 (58.4%)
Fracture location
Femur	66 (89.1%)	11 (100%)	142 (89.8%)	11 (91.6%)
Tibia	8 (10.9%)	0	16 (10.2%)	1 (8.4%)
Type of implant
Prosthesis	18 (24.3%)	2 (18.1%)	37 (23.4%)	4 (33.3%)
Intramedullary nail	53 (71.6%)	7 (63.8%)	112 (70.8%)	5 (41.6%)
Plate	3 (4.1%)	2 (18.1%)	9 (5.8%)	2 (16.7%)
Tumoral origin
Metastases	47 (55.3%)	8 (72.7%)	0	0
Primary tumour	27 (44.7%)	3 (27.3%)	0	0
Adjuvant therapy
Radiotherapy	18 (21.17%)	6 (54.5%)	0	0
Chemotherapy	15 (17.64%)	4 (36.3%)	0	0
None	41	1	158 (100%)	12 (100%)
Tromboprophylaxis
LMWH	61 (82.7%)	10 (90.9%)	129 (81.7%)	9 (75%)
Double dose LMWH	4 (5.5%)	1 (9.1%)	9 (5.7%)	2 (16.6%)
Rivaroxaban	4 (5.5%)	0	6 (3.8%)	0
Clopidogrel	5 (5.9%)	0	14 (8.8%)	1 (8.4%)